Delivery Order SPE2DB24D2106-SPE2DB25FAWJP

DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a firm fixed-price delivery order valued at $22,541.73 by the Defense Logistics Agency on September 9, 2025, for the supply of Otezla 30 mg tablets (60-count packages). The delivery order, which carries no set-aside designation, is scheduled for completion by September 10, 2025, with performance occurring in Conshohocken, Pennsylvania. This award represents a task order issued under DMS Pharmaceutical Group's larger Indefinite Delivery Contract with the DLA under the SPE2DB program, a $500 million vehicle valid through November 2026 that enables the agency to procure a comprehensive range of pharmaceutical products supporting Department of Defense healthcare facilities worldwide.

The delivery order for Otezla, a prescription medication commonly used for autoimmune conditions, reflects DMS Pharmaceutical Group's established role as a critical supplier within the federal pharmaceutical supply chain. The company's DLA contract portfolio demonstrates consistent expertise in delivering both branded and generic prescription medications, biologics, and medical consumables to military health facilities across the nation. As a woman-owned small business, DMS Pharmaceutical Group has successfully leveraged its SAM.gov registration since 2001 to compete effectively in federal procurement without requiring set-aside protections, establishing itself as a trusted partner for the Defense Logistics Agency's pharmaceutical distribution requirements.